Key Highlights
- ChromoCure describes itself as a development-stage company focused on a Chromosomal Scanner system to measure genomic characteristics associated with cancer.
- A full-text search of the SEC's EDGAR system returns no filings by ChromoCure as a registrant.
- The company shows a very large share count against a nominal market Capitalization in the low tens of thousands of dollars.
- No confirmed product launch, partnership, or regulatory event can be identified behind recent trading.
ChromoCure, Inc (OTC:KKUR) sits at the far, speculative edge of the health-technology market: a nano-cap over-the-counter security quoted at a small fraction of a penny. There is no confirmed recent catalyst, no verifiable stream of company news, and very little public financial disclosure to anchor a valuation.
Company and Latest Development
According to market-data descriptions, ChromoCure is a development-stage company focused on cancer detection technology. Its stated flagship concept is a Chromosomal Scanner system intended to measure genomic characteristics associated with cancer, alongside research into non-invasive cancer therapy approaches.
It is important to stress how little of this can be independently verified: a full-text search of the SEC's EDGAR system returns no filings by ChromoCure as a registrant, which indicates the company is not a current SEC-reporting issuer. As a result, there is no audited financial record or recent corporate filing to confirm the status of the technology.
What Is Driving Attention Around KKUR?
No single, verifiable public catalyst can be identified for KKUR. Attention around a security of this kind typically stems from its status as an ultra-low-priced OTC name rather than from concrete developments.
With shares quoted around a millionth of a dollar and an extremely small nominal market value, quoted prices reflect thin and speculative trading. Readers should not infer a product launch, partnership, or regulatory event from price movement alone.
Key Numbers and Company Position
Hard, verifiable figures are scarce. Aggregator data lists ChromoCure as a long-established but tiny entity with a very large share count and a nominal Market Capitalisation in the low tens of thousands of dollars.
Because the company does not appear to file audited reports with the SEC, these figures cannot be corroborated against primary financial statements and should be treated with caution.
What Could Come Next?
For a name like KKUR, the most meaningful potential developments would be basic ones: the resumption of transparent public disclosure, evidence of a funded, operating business, validation data for its stated diagnostic concept, or a corporate transaction such as a reverse merger.
Absent verifiable filings, there is no scheduled event, data readout, or regulatory decision that can be pointed to.
Risks to Watch
The risks are substantial and characteristic of the deep OTC market. Without current SEC reporting, investors face an acute information gap and cannot rely on audited financials. Sub-penny securities carry extreme volatility, minimal liquidity, wide spreads, and heightened exposure to dilution and to promotional activity.
The technology remains unproven in any verifiable public record, and the risk of total loss in such a security is high.
A Wide Gap Between Concept and Verifiable Substance
ChromoCure, Inc presents an intriguing stated concept in cancer detection, but for KKUR the gap between concept and verifiable substance is wide. With no confirmed SEC filings, no identifiable catalyst, and a quote resting at a fraction of a cent, the stock is defined more by its speculative micro-cap structure than by demonstrable progress.
Investors may be watching for the one thing currently missing: credible, verifiable disclosure that turns a concept into a trackable business.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...